FullText URL
Author
Nishimura, Yoshito Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID publons researchmap
Fajgenbaum, David C. Center for Cytokine Storm Treatment & Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania
Pierson, Sheila K. Center for Cytokine Storm Treatment & Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania
Iwaki, Noriko Hematology/Respiratory Medicine, Kanazawa University Graduate School of Medical Science
Nishikori, Asami Division of Pathophysiology, Okayama University Graduate School of Health Sciences
Kawano, Mitsuhiro Department of Rheumatology, Kanazawa University Graduate School of Medical Science
Nakamura, Naoya Department of Pathology, Tokai University School of Medicine
Izutsu, Koji Department of Hematology, National Cancer Center Hospital
Takeuchi, Kengo Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Nishimura, Midori Filiz Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Otsuka, Fumio Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Yoshizaki, Kazuyuki Department of Organic Fine Chemicals, Institute of Scientific and Industrial Research, Osaka University
Oksenhendler, Eric Department of Clinical Immunology, Hôpital Saint-Louis
van Rhee, Frits Myeloma Center, University of Arkansas for Medical Sciences
Sato, Yasuharu Division of Pathophysiology, Okayama University Graduate School of Health Sciences ORCID Kaken ID researchmap
Abstract
Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome is a heterogeneous entity manifesting with a constellation of symptoms described above that can occur in the context of idiopathic multicentric Castleman disease (iMCD) as well as infectious diseases, malignancies, and rheumatologic disorders. So, iMCD-TAFRO is an aggressive subtype of iMCD with TAFRO syndrome and often hyper-vascularized lymph nodes. Since we proposed diagnostic criteria of iMCD-TAFRO in 2016, we have accumulated new insights on the disorder and additional cases have been reported worldwide. In this systematic review and cohort analysis, we established and validated a definition for iMCD-TAFRO. First, we searched PubMed and Japan Medical Abstracts Society databases using the keyword “TAFRO” to extract cases. Patients with possible systemic autoimmune diseases and hematologic malignancies were excluded. Our search identified 54 cases from 50 articles. We classified cases into three categories: (1) iMCD-TAFRO (TAFRO syndrome with lymph node histopathology consistent with iMCD), (2) possible iMCD-TAFRO (TAFRO syndrome with no lymph node biopsy performed and no other co-morbidities), and (3) TAFRO without iMCD or other co-morbidities (TAFRO syndrome with lymph node histopathology not consistent with iMCD or other comorbidities). Based on the findings, we propose an international definition requiring four clinical criteria (thrombocytopenia, anasarca, fever/hyperinflammatory status, organomegaly), renal dysfunction or characteristic bone marrow findings, and lymph node features consistent with iMCD. The definition was validated with an external cohort (the ACCELERATE Natural History Registry). The present international definition will facilitate a more precise and comprehensive approach to the diagnosis of iMCD-TAFRO.
Note
This is the peer reviewed version of the following article: [Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96(10): 1241-1252. https://doi.org/10.1002/ajh.26292], which has been published in final form at [https://doi.org/10.1002/ajh.26292]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Published Date
2021-07-28
Publication Title
American Journal of Hematology
Volume
volume96
Issue
issue10
Publisher
Wiley
Start Page
1241
End Page
1252
ISSN
0361-8609
NCID
AA00520673
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
File Version
author
PubMed ID
DOI
Web of Science KeyUT
Citation
Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96(10): 1241-1252. https://doi.org/10.1002/ajh.26292
Funder Name
EUSA Pharma
Janssen Pharmaceuticals